Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Covis Pharmaceuticals announced that LANOXIN is now offered in four dosage strengths, including the new 0.0625mg and 0.1875mg strengths, for the treatment of mild-to-moderate heart failure in adults, and for the control of ventricular response rate in adult patients with chronic atrial fibrillation.
Subscribe to our email newsletter
Current dosing options of 0.250mg and 0.125mg are still available. These four convenient strengths are currently stocked in all major wholesalers.
The 2013 American College of Cardiology Foundation/American Heart Association (ACCF/AHA) Guidelines now support maintaining a Serum Digoxin Concentration (SDC) in the range of 0.5 to 0.9ng/ml. Some patients may require lower LANOXIN dosing to achieve the recommended target SDC levels.
In the Digitalis Investigation Group (DIG) study, LANOXIN was associated with a reduction in hospitalizations, including a 25% reduction in risk for the number of heart failure hospitalizations, and a 6% reduction in number of hospitalizations for any cause, while having no effect on mortality.
LANOXIN increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by improved exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality.
Where possible, LANOXIN should be used in combination with a diuretic and an angiotensin-converting enzyme (ACE) inhibitor. It is a registered trademark of the GlaxoSmithKline group of companies.